CMS has released draft guidance on the Medicare Drug Price Negotiation Program. Comments on the draft guidance are due July 2, and NCPA will be submitting comments. This draft guidance outlines new requirements for the second cycle of negotiations, which begins in 2025 and will result in maximum fair prices (MFPs) effective for 2027.